Xenomics Announces Development of a New Method for Isolation of Cell-Free Nucleic Acids From Urine

New York (ots/PRNewswire) -

- Prototype Research Kits Approach Commercialization Phase and
Target the Growing Field of Genomic-Based Molecular Diagnostics

Xenomics, Inc. (OTC Bulletin Board: XNOM; FWB:XE7), the source of
next-generation medical DNA diagnostic tests, today announced that it
has developed a new method for the isolation of low molecular weight
cell-free transrenal DNA (Tr-DNA) from urine. Using this new
approach, Xenomics is planning to develop kits for research use to
accelerate the application of its proprietary Tr-DNA technology in
different areas of DNA-based molecular diagnostics, in both humans as
well as animals.

The method is simple, cost-effective, applicable to small and
large volumes of urine, and can be used for Tr-DNA preservation,
storage, shipping and purification. Similar products will be
developed for future clinical diagnostic tests, based on analysis of
Tr-DNA.

"This new method of DNA isolation from urine specimens is an
important milestone for Xenomics, as all of our diagnostic tests
currently in development, as well as those envisioned for the future,
include this basic DNA isolation technique," commented Dr. L. David
Tomei, CEO and Co-Founder of Xenomics. "Many of the available DNA
isolation kits were designed for purification of large genomic DNA in
blood or tissue specimens. The new techniques are specifically
designed to isolate Tr-DNA from simple urine specimens, and used to
detect the genetic signature of a broad variety of diseases in the
body."

"The small DNA markers in urine specimens can come from throughout
the body and are recognized by the fact that they are clearly
distinct from the body's genetic makeup," says Dr. James Huggett,
Senior Research Fellow at The University College of London. "The
detection of pathogen genetic components as transrenal DNA has the
potential to revolutionize the diagnosis of infectious diseases like
tuberculosis. Urine is both simple and non-invasive to obtain, and
can be sampled as easily in children as in adults. The monitoring of
pathogen DNA in the urine could greatly improve the use of available
therapy and provide a valuable tool for assessing patient prognosis."

About Xenomics, Inc.

Xenomics is a molecular diagnostic company that focuses on the
development of DNA-based tests using transrenal DNA. Xenomics'
patented technology uses safe and simple urine specimens, and is
being applied to a broad range of applications including detection
and monitoring of infectious diseases, tumor detection and
therapeutic monitoring, stem cell transplantation monitoring, and
prenatal genetic testing.

Scientists from Xenomics were the first to discover that fragments
of DNA from cells throughout the body can cross the kidney barrier
and be readily detected in small urine specimens. The company
believes that its transrenal DNA technology will open significant new
markets in the molecular diagnostics field and provide a new
generation of molecular diagnostic tests. Xenomics' issued U.S.
patents protect an array of applications for molecular diagnostics
and genetic testing. The company has been joined by the National
Institute for Infectious Diseases (Istituto Nazionale per la Malattie
Infettive "Lazarus Spallanzani") in Rome, in formation of a research
and development company called SpaXen Italia, S.R.L, where clinical
researchers are focused on transrenal DNA diagnostics for a variety
of infectious diseases.

Xenomics' stock trades under the symbol XNOM.OB and is also listed
on the Frankfurt Stock Exchange under the symbol XE7.

For additional information, please visit www.xenomics.com.

Forward-Looking Statements

Certain statements made in this press release are forward looking.
Such statements are indicated by words such as "expect," "might,"
"should," "anticipate" and similar words indicating uncertainty in
facts and figures. Although Xenomics believes that the expectations
reflected in such forward-looking statements are reasonable, it can
give no assurance that such expectations reflected in such
forward-looking statements will prove to be correct. As discussed in
Xenomics' Form 10-KSB as filed with the Securities and Exchange
Commission on May 16, 2006, actual results could differ materially
from those projected in the forward-looking statements as a result of
the following factors, among others: uncertainties associated with
product development, the risk that Xenomics will not obtain approval
to market its products, the risk that Xenomics' technology will not
gain market acceptance, the risks associated with dependence upon key
personnel, and the need for additional financing.

Contact:
Xenomics, Inc.
L. David Tomei
+1-212-297-0808
ldtomei@xenomics.com
www.xenomics.com
Media Relations:
Susan Hahn
Susan Hahn & Associates
+1-212-986-6286
susanhahn@nyc.com

Web site: http://www.xenomics.com

ots Originaltext: Xenomics, Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
L. David Tomei of Xenomics, Inc., +1-212-297-0808,
ldtomei@xenomics.com; Media: Susan Hahn of Susan Hahn & Associates,
+1-212-986-6286, susanhahn@nyc.com, for Xenomics, Inc.